PULSAR Study: Serum S100B Levels in Schizophrenia Patients Treated with Sarcosine

A 6-month randomized, double-blinded, placebo-controlled study of 60 subjects with schizophrenia and predominant negative symptoms. The dataset includes serum S100B concentrations and symptom severity scores (PANSS, CDSS) measured at baseline, 6 weeks, and 6 months. The study was conducted by Agnieszka Pawlak and registered under NCT01503359.

Use Cases

• Analyze the relationship between S100B biomarker levels and clinical symptom changes based on PANSS and CDSS scores.
• Compare treatment effects between sarcosine and placebo groups on negative and general psychopathology symptoms.
• Investigate heterogeneous biomarker trajectories across affective outcome subgroups as suggested by exploratory analyses.

Strengths

• Data originates from a 6-month randomized, double-blinded, placebo-controlled trial, a robust study design.
• Includes longitudinal measurements at three time points (baseline, 6 weeks, 6 months) for 60 initial participants.
• Clinical assessments use standardized scales: the Positive and Negative Syndrome Scale (PANSS) and the Calgary Depression Scale for Schizophrenia (CDSS).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The final analyzed sample sizes (e.g., 15 in sarcosine group at 6 weeks) are smaller than the initial cohort, potentially affecting statistical power.

Provenance

Source

figshare, author Agnieszka Pawlak.

Collection Method

Data collected during the double-blind, randomized, placebo-controlled PULSAR clinical trial (NCT01503359).

Time Range

Study duration was 6 months.

Freshness

Last updated 2026-03-18 06:42:20; freshness should be verified.